The reverse split is a technical measure to avoid delisting, but does not address the underlying business fundamentals. Monitor upcoming quarterly results for revenue and cash position; the $5M market cap signals high risk of further dilution or going concern issues.
JAGX drugs
JAGX drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jaguar Health filed an 8-K announcing a 1-for-25 reverse stock split to regain compliance with Nasdaq's listing standards, effective November 24, 2026. The company initially filed a certificate for a November 23 effective date, then terminated it and refiled for November 24. The reverse split is a defensive measure to maintain its Nasdaq listing, reflecting ongoing financial distress given the $5M market cap.
Key Facts
- Board approved a 1-for-25 reverse stock split of common stock.
- Reverse split effective at 12:01 a.m. ET on November 24, 2026.
- Split intended to support compliance with Nasdaq listing standards.
- Company initially filed for Nov 23 effective date, then terminated and refiled for Nov 24.
- No change in total authorized shares of common or preferred stock.
- Fractional shares will be paid in cash in lieu of issuance.
- New CUSIP number: 47010C839.
- Market cap is $5M as of analysis time.
Financial Impact
No direct financial impact stated; reverse split reduces share count from every 25 shares to 1 share, proportionally adjusting options and warrants.
Risk Factors
- Reverse split signals financial distress and potential delisting risk if compliance is not maintained.
- Low market cap ($5M) increases vulnerability to further dilution or going concern.
- No financial data provided in this filing; fundamentals remain unclear.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-469575 |
| Document: d196905dex991.htm | 0001193125-26-469575 |
| Document: d196905dex31.htm | 0001193125-26-469575 |
| Document: d196905dex33.htm | 0001193125-26-469575 |
| Document: d196905dex32.htm | 0001193125-26-469575 |
| Document: 0001193125-26-469575-index-headers.html | 0001193125-26-469575 |
| Document: 0001193125-26-469575-index.html | 0001193125-26-469575 |
| Document: 0001193125-26-469575.txt | 0001193125-26-469575 |
Track record
33 reports on JAGX
7 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +97.54% at T+1 after the Apr 27, 2026 report. 21 of 23 went positive at some point.
Filters
- Nov 20, 20261d ago 8-K Bearish 5/10 Viewing Entry $0.2877 Now $0.2270 +21.10% settles Feb 19
- Nov 16, 20265d ago 8-K Bearish 6/10 Entry $0.3864 Now $0.2270 +41.25% settles Feb 12
- Nov 9, 202612d ago 424B5 Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
- Nov 6, 202615d ago 8-K Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
- Nov 6, 202616d ago EFFECT Bearish 5/10 Entry $0.4043 Now $0.2270 +43.85% settles Feb 4
- Nov 3, 202618d ago S-3/A Bearish 5/10 Entry $0.5575 Now $0.2270 +59.28% settles Feb 1
- Nov 3, 202618d ago 8-K Neutral 2/10 Entry $0.5575 Now $0.2270 −59.28% settles Feb 1
- Oct 29, 202623d ago DEFA14A Bearish 6/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 27
- Oct 28, 202624d ago 8-K Neutral 2/10 Entry $2.04 Now $0.2270 −88.87% settles Jan 27
- Oct 22, 20264w ago S-3 Bearish 5/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers